One Size Does Not Fit All: The Role of Vasodilating β-Blockers in Controlling Hypertension as a Means of Reducing Cardiovascular and Stroke Risk

American Journal of Medicine

Volumn 123, Issue 7 SUPPL., 2010, Pages

  Basile, Jan N ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Blockers; Efficacy; Hypertension; Nebivolol; Tolerability; Vasodilating blockers

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LABETALOL; LISINOPRIL; METOPROLOL; METOPROLOL SUCCINATE; NEBIVOLOL; NIFEDIPINE; PLACEBO; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERECTILE DYSFUNCTION; FATIGUE; GLUCOSE BLOOD LEVEL; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MALE SEXUAL DYSFUNCTION; METABOLIC SYNDROME X; MONOTHERAPY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; BENZOPYRANS; ETHANOLAMINES; HUMANS; HYPERTENSION; RISK ASSESSMENT; STROKE; VASODILATOR AGENTS;

EID: 77953678744     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2010.04.013     Document Type: Article

References (39)

1. Chobanian A.V., Bakris G.L., Black H.R., et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
2. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 (2002) 995-1003
3. Dahlöf B., Sever P.S., Poulter N.R., et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
4. Messerli F.H., Bangalore S., and Julius S. Risk/benefit assessment of β-blockers and diuretics precludes their use as first-line therapy in hypertension. Circulation 117 (2008) 2706-2715
5. Carlberg B., Samuelsson O., and Lindholm L.H. Atenolol in hypertension: is it a wise choice?. Lancet 364 (2004) 1684-1689
6. Sarafidis P.A., and Bakris G.L. Metabolic effects of β-blockers: importance of dissociating newer from conventional agents. J Hypertens 25 (2007) 249-252
7. Pedersen M.E., and Cockcroft J.R. The vasodilatory beta-blockers. Curr Hypertens Rep 9 (2007) 269-277
8. Weiss R.J., Weber M.A., Carr A.A., and Sullivan W.A. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich) 9 (2007) 667-676
9. Saunders E., Smith W.B., DeSalvo K.B., and Sullivan W.A. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich) 9 (2007) 866-875
10. Greathouse M. Nebivolol efficacy and safety in patients with stage I-II hypertension. Clin Cardiol 33 (2010) E20-E27
11. Carr A.A., and Weiss R.J. Significant blood pressure-lowering responses in nebivolol-treated patients assessed using stringent, clinically relevant criteria. J Clin Hypertens (Greenwich) 10 suppl A (2008) A117-A118
12. 1-blocker nebivolol in patients without an initial response. J Clin Hypertens (Greenwich) 10 suppl A (2008) A124-A125
13. Gradman A.H. Safety and tolerability of nebivolol: a pooled safety analysis comparing typical β-blocker-associated adverse events with those of placebo. J Clin Hypertens (Greenwich) 10 suppl A (2008) A120
14. Sowers J., and Whaley-Connell A. Long-term effects of the novel β-blocker, nebivolol, on blood glucose in hypertensive patients. South Med J 101 (2008) 863
15. Giles T. Glucose control in hypertensive patients treated with the vasodilating, selective β-blocker, nebivolol. South Med J 101 (2008) 863
16. Bakris G.L., Fonseca V., Katholi R.E., et al., GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292 (2004) 2227-2236
17. Flather M.D., Shibata M.C., Coats A.J.S., et al., SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
18. Packer M., Coats A.J.S., Fowler M.B., et al., Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
19. Rosamond W., Flegal K., Friday G., et al., American Heart Association Statistics Committee and Stroke Statistics Committee. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
20. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 304 (1992) 405-412
21. Messerli F.H., Grossman E., and Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?. A systematic review. JAMA 279 (1998) 1903-1907
22. Lindholm L.H., Carlberg B., and Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension?. A meta-analysis. Lancet 366 (2005) 1545-1553
23. Williams B., Lacy P.S., Thom S.M., et al., CAFE Investigators, the Anglo-Scandinavian Cardiac Outcomes Trial Investigators, and the CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 (2006) 1213-1225
24. Wiysonge C.S., Bradley H., Mayosi B.M., et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 1 (2007) CD002003
25. Cutler J.A., and Davis B.R. Thiazide-type diuretics and β-adrenergic blockers as first-line drug treatments for hypertension. Circulation 117 (2008) 2691-2705
26. Kamp O., Sieswerda G.T., and Visser C.A. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 92 (2003) 344-348
27. 1-adrenergic receptor selectivity of nebivolol and various other β-blockers in human myocardium. Am J Hypertens 18 suppl 4s (2005) 51A-52A
28. Brixius K., Bundkirchen A., Bölck B., Melhorn U., and Schwinger R.H.G. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 133 (2001) 1330-1338
29. Mason R.P., Kalinowski L., Jacob R.F., Jacoby A.M., and Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 112 (2005) 3795-3801
30. Ignarro L.J. Experimental activity of nitric oxide-dependent vasodilatory activity of nebivolol, a third generation β-blocker. Blood Press Suppl 1 (2004) 3-17
31. Taylor A.A., and Bakris G.L. The role of vasodilating β-blockers in patients with hypertension and the cardiometabolic syndrome. Am J Med 123 suppl (2010) S21-S26
32. Giles T.D. The role of vasodilating β-blockers in patients with complicated hypertension: focus on nebivolol. Am J Med 123 suppl (2010) S16-S20
33. Cushman W.C., Ford C.E., Cutler J.A., et al., ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 4 (2002) 393-404
34. Neutel J.M., Smith D.H., and Gradman A.H. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension. J Hum Hypertens 24 (2010) 64-73
35. Lacourcière Y., Lefebvre J., Poirier L., Archambault F., and Arnott W. A double-blind crossover comparison of nebivolol and lisinopril in the treatment of ambulatory hypertension. Am J Ther 1 (1994) 74-80
36. Lacourcière Y., Poirier L., Lefebvre J., Provencher P., and Arnott W. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol 32 (1992) 660-666
37. Uhlir O., Fejfusa M., Havranek K., et al. Nebivolol vs metoprolol in the treatment of hypertension. Drug Invest 3 suppl 1 (1991) 107-110
38. Brixius K., Middeke M., Lichtenthal A., Jahn E., and Schwinger R.H. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 34 (2007) 327-331
39. Celik T., Iyisoy A., Kursaklioglu H., et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 24 (2006) 591-596